KURATA Morito

J-GLOBAL         Last updated: Dec 7, 2019 at 03:01
 
Avatar
Name
KURATA Morito
Affiliation
Tokyo Medical and Dental University
Section
Graduate School of Medical and Dental Sciences Medical and Dental Sciences Advanced Therapeutic Sciences Comprehensive Pathology
Job title
Junior Associate Professor

Research Areas

 
 

Published Papers

 
Kitagawa M, Kurata M, Onishi I, Yamamoto K
Pathology international      Nov 2019   [Refereed]
Yamamoto K, Abe S, Honda A, Hashimoto J, Aizawa Y, Ishibashi S, Takemura T, Hanagata N, Yamamoto M, Miura O, Kurata M, Kitagawa M
Laboratory investigation; a journal of technical methods and pathology      Sep 2019   [Refereed]
Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma
Nogawa Daichi, Gulinisha Aihemaiti, Yamamoto Akiko, Onishi Iichiroh, Kurata Morito, Miyasaka Naoyuki, Yamamoto Kohei, Kitagawa Masanobu
CANCER SCIENCE   109 503-503   Dec 2018   [Refereed]
Ranolazine is a potential anti-tumor reagent against refractory cases in malignant lymphoma
Yamamoto Kohei, Abe Shinya, Kurata Morito, Honda Ayaka, Yamamoto Masahide, Kitagawa Masanobu
CANCER SCIENCE   109 494-494   Dec 2018   [Refereed]
Controllable NRAS expression system and analysis of different signals
Kurata Morito, Yamamoto Kohei, Kitagawa Masanobu
CANCER SCIENCE   109 895-895   Dec 2018   [Refereed]

Misc

 
Morito Kurata, Kouhei Yamamoto, Branden S Moriarity, Masanobu Kitagawa, David A Largaespada
J. Hum. Genet.   63(2) 179-186   Feb 2018   [Refereed][Invited]
CRISPR/Cas9-based tools have rapidly developed in recent years. These include CRISPR-based gene activation (CRISPRa) or inhibition (CRISPRi), for which there are libraries. CRISPR libraries for loss of function have been widely used to identify ne...
Kouhei Yamamoto, Yukako Miwa, Shiho Abe-Suzuki, Shinya Abe, Susumu Kirimura, Iichiroh Onishi, Masanobu Kitagawa, Morito Kurata
Mol Med Rep   13(1) 587-591   Jan 2016   [Refereed]
Extramedullary hematopoiesis (EMH) occurs under various circumstances, including during embryonic/developmental periods, pathological status secondary to insufficient bone marrow function or ineffective hematopoiesis, in hematological disorders, f...

Conference Activities & Talks

 
卵巣癌におけるMCM2タンパクの細胞内局在に着目した臨床病理学的検討(Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma)
野川 大地, グリニサ・アヒマティ , 山本 阿紀子, 立澤 杏奈, 峰尾 竜徳, 大西 威一郎, 倉田 盛人, 宮坂 尚幸, 山本 浩平, 北川 昌伸
日本病理学会会誌   1 Apr 2019   (一社)日本病理学会
ラノラジンは難治性悪性リンパ腫に対する有望な抗腫瘍薬としての可能性を有する(Ranolazine is a potential anti-tumor reagent against refractory cases in malignant lymphoma)
山本 浩平, 阿部 晋也, 本田 彩華, 山本 正英, 三浦 修, 倉田 盛人, 北川 昌伸
日本病理学会会誌   1 Apr 2019   (一社)日本病理学会
卵巣癌におけるMCM2タンパクの細胞内局在に着目した臨床病理学的検討(Subcellular localization of MCM2 correlates with the prognosis of ovarian clear cell carcinoma)
野川 大地, グリニサ・アヒマティ , 山本 阿紀子, 大西 威一郎, 倉田 盛人, 宮坂 尚幸, 山本 浩平, 北川 昌伸
日本癌学会総会記事   1 Sep 2018   日本癌学会
ラノラジンは難治性悪性リンパ腫に対する有望な抗腫瘍薬としての可能性を有する(Ranolazine is a potential anti-tumor reagent against refractory cases in malignant lymphoma)
山本 浩平, 阿部 晋也, 倉田 盛人, 本田 彩華, 山本 正英, 北川 昌伸
日本癌学会総会記事   1 Sep 2018   日本癌学会
NRAS発現調整可能システムとシグナルの解析(Controllable NRAS expression system and analysis of different signals)
倉田 盛人, 山本 浩平, 北川 昌伸
日本癌学会総会記事   1 Sep 2018   日本癌学会